SSY Group Limited (HKEX: 02005) has announced that on June 4, 2026, its wholly-owned subsidiary, Shijiazhuang No.4 Pharmaceutical Co., Ltd., entered into a letter of intent with Anhui Xin Zheng He Ying Pharmaceutical Technology Co., Ltd. regarding a potential collaboration for two Category 2 chemical improved new drugs.
The collaboration covers two specific products: one is a Class 2.2 antispasmodic drug intended for pediatric use, and the other is a Class 2.3 drug targeting Chronic Obstructive Pulmonary Disease (COPD).
As per the terms outlined in the letter of intent, Xin Zheng He Ying will be responsible for completing the entire research scope of the project. This includes all pharmaceutical research data, non-clinical study materials, registration and application documentation, and associated intellectual property.
Xin Zheng He Ying is to transfer all project-related technology and know-how, relevant patents (including application rights), registration data, and exclusive global commercialization rights in their entirety to Shijiazhuang No.4 Pharmaceutical.
Upon the execution of a formal contract and the payment of an initial sum by Shijiazhuang No.4 Pharmaceutical, all intellectual property rights, Marketing Authorization Holder (MAH) qualifications, and commercial benefits pertaining to the project will become the sole property of Shijiazhuang No.4 Pharmaceutical.
Xin Zheng He Ying will retain authorship rights, where applicable, and retains the right to receive milestone payments.
The successful realization of this project is expected to enable the group to acquire and benefit from the exclusive technology, proprietary knowledge, relevant patents, registration data, and global commercialization rights. This development is anticipated to positively influence the group's future growth and business expansion.
Comments